Compare Annaly Capital Management, Inc. (NLY) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Vir Biotechnology Inc. Common Stock — how do they compare? Annaly Capital Management, Inc. trades at $18.22 (market cap $13.69B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Annaly Capital Management, Inc. is far larger — about 7.6× Vir Biotechnology Inc. Common Stock's market cap, and Annaly Capital Management, Inc. pays a 16.52% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Annaly Capital Management, Inc. for 92 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| NLY | VIR | |
|---|---|---|
Market Cap | $13.69B | $1.80B |
Volume | 11,361,415 | 1,782,836 |
Sector | Real Estate | Health |
52-Week High | $24.40 | $11.78 |
52-Week Low | $17.93 | $5.12 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $135.72B | $1.36B |
Dividend Yield | 16.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Annaly Capital Management (NLY) trades at $18.16, down 0.71% with a bearish technical outlook despite strong fundamentals. The mortgage REIT shows robust profitability with 92.77% net income margin and 20.66% ROE, trading below book value at P/B of 0.91. Recent earnings beats and a $0.75 quarterly dividend yielding approximately 16.5% highlight income appeal, though cash flow volatility and rising leverage pose concerns.
NLY presents a high-yield opportunity with significant analyst upside to $22 consensus target, but faces headwinds from interest rate sensitivity and portfolio expansion risks. The stock's attractive valuation and dividend sustainability must be weighed against mREIT sector volatility and the company's substantial debt load increasing to 23.55 debt-to-asset ratio in 2025.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Vir Biotechnology Inc. Common Stock
Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →
